Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Tumor-Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma.

Alcedo KP, Guerrero A, Basrur V, Fu D, Richardson ML, McLane JS, Tsou CC, Nesvizhskii AI, Welling TH, Lebrilla CB, Otey CA, Kim HJ, Omary MB, Snider NT.

Hepatol Commun. 2019 Aug 9;3(10):1400-1414. doi: 10.1002/hep4.1410. eCollection 2019 Oct.

2.

Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.

Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, Park JS, Dagher NN, Taslakian B, Hickey RM.

J Vasc Interv Radiol. 2019 Aug 14. pii: S1051-0443(19)30508-1. doi: 10.1016/j.jvir.2019.05.023. [Epub ahead of print]

PMID:
31422022
3.

Histotripsy for Non-Invasive Ablation of Hepatocellular Carcinoma (HCC) Tumor in a Subcutaneous Xenograft Murine Model.

Worlikar T, Vlaisavljevich E, Gerhardson T, Greve J, Wan S, Kuruvilla S, Lundt J, Ives K, Hall T, Welling TH, Lee F, Xu Z.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:6064-6067. doi: 10.1109/EMBC.2018.8513650.

PMID:
30441719
4.

Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.

Welling TH, Eddinger K, Carrier K, Zhu D, Kleaveland T, Moore DE, Schaubel DE, Abt PL.

Liver Transpl. 2018 Sep;24(9):1233-1242. doi: 10.1002/lt.25194.

5.

Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.

Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS.

JAMA Oncol. 2018 Jan 1;4(1):40-47. doi: 10.1001/jamaoncol.2017.2303.

6.

Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model.

Vlaisavljevich E, Owens G, Lundt J, Teofilovic D, Ives K, Duryea A, Bertolina J, Welling TH, Xu Z.

Ultrasound Med Biol. 2017 Jun;43(6):1237-1251. doi: 10.1016/j.ultrasmedbio.2017.01.016. Epub 2017 Mar 17.

PMID:
28318889
7.

GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer.

Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, Schradle KA, Urs S, Pasca Di Magliano M, Welling TH, Palmbos PL, Abel EV, Sahai V, Nagrath S, Wang L, Simeone DM.

Cancer Discov. 2016 Aug;6(8):886-99. doi: 10.1158/2159-8290.CD-15-0947. Epub 2016 May 16.

8.

Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model.

Vlaisavljevich E, Greve J, Cheng X, Ives K, Shi J, Jin L, Arvidson A, Hall T, Welling TH, Owens G, Roberts W, Xu Z.

Ultrasound Med Biol. 2016 Aug;42(8):1890-902. doi: 10.1016/j.ultrasmedbio.2016.03.018. Epub 2016 Apr 29.

9.

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, Chinnaiyan AM, Welling TH, Marquez V, Kotarski J, Wang H, Wang Z, Zhang Y, Liu R, Wang G, Zou W.

Nat Immunol. 2016 Jan;17(1):95-103. doi: 10.1038/ni.3313. Epub 2015 Nov 2.

10.

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS.

Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14.

11.

Myeloid cells in hepatocellular carcinoma.

Wan S, Kuo N, Kryczek I, Zou W, Welling TH.

Hepatology. 2015 Oct;62(4):1304-12. doi: 10.1002/hep.27867. Epub 2015 Jul 1. Review.

12.

Internal biliary stenting during orthotopic liver transplantation: anastomotic complications, post-transplant biliary interventions, and survival.

Mathur AK, Nadig SN, Kingman S, Lee D, Kinkade K, Sonnenday CJ, Welling TH.

Clin Transplant. 2015 Apr;29(4):327-35. doi: 10.1111/ctr.12518. Epub 2015 Feb 23.

13.

Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis.

Thakolwiboon S, Zhu J, Liang Q, Welling TH, Zhang M, Lubman DM.

J Proteomics Bioinform. 2014 Sep 12;7(10):296-302.

14.

Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).

Snider NT, Altshuler PJ, Wan S, Welling TH, Cavalcoli J, Omary MB.

Mol Biol Cell. 2014 Dec 15;25(25):4024-33. doi: 10.1091/mbc.E14-06-1167. Epub 2014 Oct 8.

15.

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH.

Gastroenterology. 2014 Dec;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039. Epub 2014 Aug 30.

16.

CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice.

Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, di Magliano MP.

Cancer Immunol Res. 2014 May;2(5):423-35. doi: 10.1158/2326-6066.CIR-14-0016-T. Epub 2014 Feb 11.

17.

Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.

Welling TH, Feng M, Wan S, Hwang SY, Volk ML, Lawrence TS, Zalupski MM, Sonnenday CJ.

Liver Transpl. 2014 Jan;20(1):81-8. doi: 10.1002/lt.23757. Epub 2013 Nov 21.

18.

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

Crespo J, Sun H, Welling TH, Tian Z, Zou W.

Curr Opin Immunol. 2013 Apr;25(2):214-21. doi: 10.1016/j.coi.2012.12.003. Epub 2013 Jan 6. Review.

19.

Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival.

Welling TH, Fu S, Wan S, Zou W, Marrero JA.

Cancer Invest. 2012 Dec;30(10):689-97. doi: 10.3109/07357907.2012.732161. Epub 2012 Oct 16.

PMID:
23072563
20.

c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM.

Gastroenterology. 2011 Dec;141(6):2218-2227.e5. doi: 10.1053/j.gastro.2011.08.009. Epub 2011 Aug 22.

PMID:
21864475
21.

The effect of smoking on biliary complications following liver transplantation.

Mathur AK, Ranney DN, Patel SP, Lee DS, Bednar F, Lynch RJ, Welling TH, Englesbe MJ.

Transpl Int. 2011 Jan;24(1):58-66. doi: 10.1111/j.1432-2277.2010.01146.x.

22.

Body mass index and adverse perioperative outcomes following hepatic resection.

Mathur AK, Ghaferi AA, Osborne NH, Pawlik TM, Campbell DA, Englesbe MJ, Welling TH.

J Gastrointest Surg. 2010 Aug;14(8):1285-91. doi: 10.1007/s11605-010-1232-9. Epub 2010 Jun 8.

23.

Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy.

Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH.

J Gastrointest Surg. 2010 May;14(5):849-57. doi: 10.1007/s11605-010-1163-5. Epub 2010 Feb 6.

PMID:
20140536
24.

The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre.

Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA.

Aliment Pharmacol Ther. 2010 Mar;31(6):625-33. doi: 10.1111/j.1365-2036.2009.04218.x. Epub 2009 Dec 10.

25.

Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.

Wu K, Kryczek I, Chen L, Zou W, Welling TH.

Cancer Res. 2009 Oct 15;69(20):8067-75. doi: 10.1158/0008-5472.CAN-09-0901. Epub 2009 Oct 13.

26.

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W.

Blood. 2009 Aug 6;114(6):1141-9. doi: 10.1182/blood-2009-03-208249. Epub 2009 May 21.

27.

FOXP3 defines regulatory T cells in human tumor and autoimmune disease.

Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W.

Cancer Res. 2009 May 1;69(9):3995-4000. doi: 10.1158/0008-5472.CAN-08-3804. Epub 2009 Apr 21.

28.

Role of liver transplantation in the treatment of cholangiocarcinoma.

Singal A, Welling TH, Marrero JA.

Expert Rev Anticancer Ther. 2009 Apr;9(4):491-502. doi: 10.1586/era.09.5. Review.

PMID:
19374602
29.

Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.

Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT, Zou W.

J Immunol. 2008 Oct 1;181(7):4733-41.

30.

Hepatopulmonary syndrome: use of extracorporeal life support for life-threatening hypoxia following liver transplantation.

Fleming GM, Cornell TT, Welling TH, Magee JC, Annich GM.

Liver Transpl. 2008 Jul;14(7):966-70. doi: 10.1002/lt.21477.

31.

Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.

Welling TH, Lu G, Csencsits K, Wood SC, Jarvinen L, Bishop DK.

Surgery. 2008 Mar;143(3):394-403. doi: 10.1016/j.surg.2007.09.040. Epub 2007 Dec 21.

32.

Biliary complications following liver transplantation in the model for end-stage liver disease era: effect of donor, recipient, and technical factors.

Welling TH, Heidt DG, Englesbe MJ, Magee JC, Sung RS, Campbell DA, Punch JD, Pelletier SJ.

Liver Transpl. 2008 Jan;14(1):73-80.

33.

Financial implications of pancreas transplant complications: a business case for quality improvement.

Cohn JA, Englesbe MJ, Ads YM, Paruch JL, Pelletier SJ, Welling TH, Sonnenday CJ, Magee JC, Punch JD, Campbell DA Jr, Sung RS.

Am J Transplant. 2007 Jun;7(6):1656-60. Epub 2007 Apr 8.

34.

Who pays for biliary complications following liver transplant? A business case for quality improvement.

Englesbe MJ, Dimick J, Mathur A, Ads Y, Welling TH, Pelletier SJ, Heidt DG, Magee JC, Sung RS, Punch JD, Hanto DW, Campbell DA Jr.

Am J Transplant. 2006 Dec;6(12):2978-82.

35.

Renal artery aneurysms: a 35-year clinical experience with 252 aneurysms in 168 patients.

Henke PK, Cardneau JD, Welling TH 3rd, Upchurch GR Jr, Wakefield TW, Jacobs LA, Proctor SB, Greenfield LJ, Stanley JC.

Ann Surg. 2001 Oct;234(4):454-62; discussion 462-3.

36.

Adenoviral-mediated gene transfer of ICP47 inhibits major histocompatibility complex class I expression on vascular cells in vitro.

Furukawa L, Brevetti LS, Brady SE, Johnson D, Ma M, Welling TH, Messina LM.

J Vasc Surg. 2000 Mar;31(3):558-66.

37.
39.

Transforming growth factor-beta 1 increases lysyl oxidase enzyme activity and mRNA in rat aortic smooth muscle cells.

Shanley CJ, Gharaee-Kermani M, Sarkar R, Welling TH, Kriegel A, Ford JW, Stanley JC, Phan SH.

J Vasc Surg. 1997 Mar;25(3):446-52.

40.

Induction of angiogenesis by lidocaine and basic fibroblast growth factor: a model for in vivo retroviral-mediated gene therapy.

Jejurikar SS, Welling TH, Zelenock JA, Gordon D, Burkel WE, Carlson BM, Messina LM.

J Surg Res. 1997 Feb 1;67(2):137-46.

PMID:
9073560
41.
42.
43.
45.

Inhibition of aortic aneurysm development in blotchy mice by beta adrenergic blockade independent of altered lysyl oxidase activity.

Moursi MM, Beebe HG, Messina LM, Welling TH, Stanley JC.

J Vasc Surg. 1995 May;21(5):792-9; discussion 799-800.

46.
47.

Pulmonary endothelial cell ATP depletion following intestinal ischemia.

Gerkin TM, Welling TH, Turnage RH, Ryan US, Guice KS, Oldham KT.

J Surg Res. 1992 Jun;52(6):642-7.

Supplemental Content

Loading ...
Support Center